FDA Overhauls Human Factors Guidance: New Submission Category Introduced

FDA Overhauls Human Factors Guidance: New Submission Category Introduced

The FDA has updated its human factors guidance, introducing new risk-based submission categories and expanding examples for modified devices. The revision provides clearer frameworks for manufacturers regarding the human factors information required in premarket submissions. For device makers navigating CDRH review, the changes carry immediate implications for development timelines, regulatory strategy, and resource allocation heading into the second half of 2026.

Key Takeaways

• The FDA introduced a new "Category 2" submission pathway that streamlines human factors requirements for sponsors with established device platforms where critical tasks exist but full validation isn't required under specific use-related risk assessment conditions.
• The revised guidance, titled Content of Human Factors Information in Medical Device Marketing Submissions, builds on and replaces the 2022 draft, expanding examples for modified devices and clarifying documentation expectations for premarket submissions to CDRH.
• Manufacturers have until August 1, 2026, before the FDA fully operationalizes the new framework — a grace period offering a strategic window to align HFE/UE strategies with the updated categories.
• The FDA is also proposing statutory changes to clarify its authority to enforce pre-notification requirements for manufacturing changes — including process, site, and API supplier changes — that could substantially affect safety and efficacy.
• The changes signal a shift toward risk-proportionate HFE/UE review, with direct consequences for regulatory pathways and development resource planning across the medical device sector.

What Changed in the FDA's Revised Human Factors Guidance Framework?

The U.S. Food and Drug Administration has issued a revised guidance document titled Content of Human Factors Information in Medical Device Marketing Submissions. The update builds on the 2022 draft and introduces a more defined, risk-based framework for human factors engineering and usability engineering (HFE/UE) information submitted to the Center for Devices and Radiological Health (CDRH).

The most consequential addition is the "Category 2" submission pathway. It targets manufacturers with established device platforms — those where critical user tasks have been identified but, under specific use-related risk assessment (URRA) conditions, do not require full validation testing. The FDA designed this pathway to reduce redundant burden on sponsors who can demonstrate a sufficient safety profile through existing data, provided their risk documentation meets the agency's threshold.

The guidance also expands examples for modified devices, addressing a gray area that has long frustrated regulatory affairs teams. When a device undergoes iterative changes — whether to software interfaces, physical controls, or labeling — determining the scope of new human factors data required has been inconsistent. The revised document provides clearer boundary conditions for when modified devices trigger additional HFE/UE testing versus when prior data suffices.

The FDA has signaled a 60-day operationalization window. For submissions currently pending or received before August 1, 2026, the agency generally does not expect manufacturers to have incorporated the newly recommended information. However, it will review such information if voluntarily included — suggesting that early adopters of the framework could gain a review efficiency advantage.

How Will the New Submission Categories Impact Device Manufacturers?

The updated guidance has direct implications for medical device manufacturers preparing premarket submissions. The introduction of new submission categories, particularly Category 2, offers potential efficiencies for companies leveraging existing technologies with well-characterized user interfaces. For these sponsors, the pathway could reduce validation study scope, compress submission preparation timelines, and lower HFE/UE-related development costs.

But the opportunity comes with compliance complexity. Manufacturers must now assess their devices against a tiered category system and determine which pathway applies. Misclassification — or insufficient documentation to justify a streamlined category — could trigger additional information requests and delay review cycles. Regulatory affairs and human factors teams will need to coordinate earlier in development to align submission strategy with the new framework.

The changes signal the FDA's move toward a more nuanced, risk-proportionate approach to HFE/UE review. Companies that invest in understanding the category thresholds now stand to benefit from smoother submissions. Those that treat this as a routine guidance update without adjusting internal HFE/UE workflows risk falling out of step with reviewer expectations by the August implementation date.

How Does the FDA's Risk-Based Category Framework Work?

The core of the revised guidance lies in its risk-based submission categories. This framework tailors the level of required HFE/UE information to the specific risks associated with a device and its use environment. While the full details are elaborated within the guidance document, the tiered structure follows a graduated approach: higher-risk devices with novel user interactions face the most rigorous validation requirements, while established platforms with well-understood critical tasks may qualify for streamlined pathways.

Category 2 specifically addresses scenarios where critical tasks exist but validation is not required — contingent on the sponsor's URRA demonstrating that residual risks are adequately controlled through other means, such as labeling, training, or design safeguards. This is not a blanket exemption. Manufacturers must still document their risk analysis comprehensively and justify why full validation testing would not meaningfully reduce use-related risk.

For sponsors, the practical takeaway is straightforward: invest in early and rigorous URRA. The quality of that risk assessment will now directly determine which submission pathway applies — and how much HFE/UE data the FDA expects to see in a marketing submission.

What Should Manufacturers Know About Human Factors Requirements for Combination Products?

While the primary focus of the updated guidance is on medical devices, its principles extend to combination products. For products integrating a drug, biologic, and device component, human factors requirements apply to both the device constituent and the overall product system. The FDA's emphasis on risk-based approaches and clear documentation in marketing submissions is directly relevant here.

Manufacturers of combination products should review the updated guidance to ensure their HFE/UE strategies address the unique challenges of integrated systems — particularly drug delivery mechanisms and device-drug interface usability. The interaction between a user and a combination product often introduces use-related risks that differ from standalone devices, and the FDA's framework expects those risks to be captured in the submission's human factors documentation.

What Are the Proposed Statutory Changes to FDA Authority?

Beyond the human factors guidance itself, the FDA is proposing statutory changes to clarify its authority to enforce pre-notification requirements for manufacturing changes. These include changes to manufacturing processes and sites, changes to API suppliers, and other manufacturing modifications with substantial potential to affect safety and efficacy. While distinct from the HFE/UE guidance update, these broader regulatory moves reflect the agency's push toward greater upstream visibility into changes that could impact product quality and patient safety. The statutory proposals, if finalized, would strengthen the FDA's ability to require advance notification — shifting the posture from reactive review to proactive oversight for a defined set of manufacturing changes.

Frequently Asked Questions

Related coverage

• FDA to Issue Guidance on Animal-Derived Thyroid Products by August 2026, Signaling Regulatory Shift
• FDA Guidance on Next-Gen Sequencing for Gene Therapy Safety